{"id":"NCT01712438","sponsor":"Octapharma","briefTitle":"Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients","officialTitle":"Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2018-12-14","completion":"2019-12-20","firstPosted":"2012-10-23","resultsPosted":"2019-10-21","lastUpdate":"2021-01-19"},"enrollment":110,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Human cl rhFVIII","otherNames":[]}],"arms":[{"label":"Human cl rhFVIII","type":"EXPERIMENTAL"}],"summary":"Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.","primaryOutcome":{"measure":"Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors","timeFrame":"maximum 5 years (100 exposure days)","effectByArm":[{"arm":"SAF/ITT Population","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":37,"countries":["United States","Belarus","Canada","France","Georgia","Germany","India","Italy","Moldova","Morocco","Poland","Portugal","Russia","Slovenia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":108},"commonTop":["Pyrexia","Nasopharyngitis","Factor VIII inhibition","Anaemia","Rhinitis"]}}